E-cadherin-Fc chimera protein matrix enhances cancer stem-like properties and induces mesenchymal features in colon cancer cells.
Aldehyde Dehydrogenase
/ metabolism
Antineoplastic Agents
/ pharmacology
Cell Line, Tumor
Colonic Neoplasms
/ metabolism
Drug Resistance, Neoplasm
ErbB Receptors
Fluorouracil
/ pharmacology
Humans
Hyaluronan Receptors
/ metabolism
Immunoglobulin Fc Fragments
Neoplastic Stem Cells
/ metabolism
Ornithine Decarboxylase
Oxaliplatin
/ pharmacology
Polycomb Repressive Complex 1
/ metabolism
Proteasome Endopeptidase Complex
/ metabolism
Receptors, G-Protein-Coupled
/ metabolism
Recombinant Fusion Proteins
/ metabolism
SOX9 Transcription Factor
/ metabolism
Spheroids, Cellular
E-cadherin-Fc
cancer stem cell
colon cancer
epithelial-mesenchymal transition
extracellular matrix
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
01
05
2019
revised:
23
08
2019
accepted:
30
08
2019
pubmed:
11
9
2019
medline:
13
11
2019
entrez:
11
9
2019
Statut:
ppublish
Résumé
Cancer stem cells (CSC) are a subpopulation of tumor cells with properties of high tumorigenicity and drug resistance, which lead to recurrence and poor prognosis. Although a better understanding of CSC is essential for developing cancer therapies, scarcity of the CSC population has hindered such analyses. The aim of the present study was to elucidate whether the E-cadherin-Fc chimera protein (E-cad-Fc) enhances cancer stem-like properties because studies show that soluble E-cadherin stimulates human epithelial growth factor receptor (EGFR) and downstream signaling pathways that are reported to play a crucial role in CSC. For this purpose, we used ornithine decarboxylase (ODC)-degron-transduced (Degron(+)) KM12SM cells as a CSC model that retains relatively low CSC properties. Compared to cultures without E-cad-Fc treatment, we found that E-cad-Fc treatment further suppressed proteasome activity and largely enhanced cancer stem-like properties of ODC-degron-transduced KM12SM cells. These results include increased expression of stem cell markers Lgr5, Bmi-1, SOX9, CD44, and CD44v9, aldehyde dehydrogenase (ALDH), and enhancement of robust spheroid formation, and chemoresistance to 5-fluorouracil (5-FU) and oxaliplatin (L-OHP). These effects could be attributed to activation of the EGFR pathway as identified by extensive phosphorylation of EGFR, ERK, PI3K, AKT, and mTOR. In SW480 cells, E-cad-Fc matrix induced some CSC markers such as CD44v9 and ALDH. We also found that E-cad-Fc matrix showed high efficiency of inducing mesenchymal changes in colon cancer cells. Our data suggest that the E-cad-Fc matrix may enhance CSC properties such as enhancement of chemoresistance and sphere formation.
Identifiants
pubmed: 31505062
doi: 10.1111/cas.14193
pmc: PMC6825015
doi:
Substances chimiques
Antineoplastic Agents
0
BMI1 protein, human
0
CD44 protein, human
0
Hyaluronan Receptors
0
Immunoglobulin Fc Fragments
0
LGR5 protein, human
0
Receptors, G-Protein-Coupled
0
Recombinant Fusion Proteins
0
SOX9 Transcription Factor
0
SOX9 protein, human
0
Oxaliplatin
04ZR38536J
Aldehyde Dehydrogenase
EC 1.2.1.3
Polycomb Repressive Complex 1
EC 2.3.2.27
ErbB Receptors
EC 2.7.10.1
Proteasome Endopeptidase Complex
EC 3.4.25.1
Ornithine Decarboxylase
EC 4.1.1.17
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3520-3532Subventions
Organisme : Rotary Yoneyama Memorial Foundation
ID : RY036688
Organisme : Kagoshima Shinsangyo Sousei Investment Limited Partnership
Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
J Natl Cancer Inst. 2014 Feb;106(2):djt373
pubmed: 24491301
Pharmacol Ther. 2016 Apr;160:145-58
pubmed: 26899500
Oncogene. 2014 Jan 9;33(2):225-35
pubmed: 23318419
J Pharm Sci. 2017 Sep;106(9):2642-2649
pubmed: 28322937
Clin Exp Metastasis. 2013 Feb;30(2):189-200
pubmed: 22930170
J Clin Med. 2017 Dec 22;7(1):
pubmed: 29271928
Mol Cancer. 2012 Nov 23;11:87
pubmed: 23174018
Methods Mol Biol. 2012;916:373-85
pubmed: 22914954
Int J Cancer. 2016 Jun 15;138(12):2804-12
pubmed: 26704932
Cancer Med. 2012 Aug;1(1):5-16
pubmed: 23342249
Tumour Biol. 2014 May;35(5):3945-51
pubmed: 24420150
Cancer Metastasis Rev. 2009 Jun;28(1-2):15-33
pubmed: 19169796
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
FEBS J. 2013 May;280(9):2027-41
pubmed: 23461856
Sci Rep. 2017 Feb 08;7:41838
pubmed: 28176811
Ann Transl Med. 2016 Dec;4(24):519
pubmed: 28149881
Oncol Lett. 2014 Jun;7(6):1936-1940
pubmed: 24932263
Cell Mol Gastroenterol Hepatol. 2017 Mar 14;4(1):55-63
pubmed: 28560289
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
J Appl Genet. 2008;49(2):193-9
pubmed: 18436993
Acta Anat (Basel). 1995;154(1):8-20
pubmed: 8714286
J Cancer. 2017 Sep 30;8(17):3555-3566
pubmed: 29151941
Cancer Res. 2008 May 15;68(10):3645-54
pubmed: 18483246
Mol Cancer Res. 2018 Feb;16(2):286-295
pubmed: 29117943
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Differentiation. 2011 Sep;82(2):89-98
pubmed: 21596473
Oncogene. 2013 Oct 31;32(44):5191-8
pubmed: 23334333
Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):466-71
pubmed: 22190486
Mol Cancer. 2012 Sep 25;11:73
pubmed: 23009336
Kurume Med J. 1998;45(1):121-5
pubmed: 9658761
J Mater Chem B. 2016 Jun 28;4(24):4267-4277
pubmed: 32263408
Hum Reprod. 2003 Jul;18(7):1404-9
pubmed: 12832363
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15526-31
pubmed: 25313085
Clin Cancer Res. 2016 Nov 1;22(21):5277-5286
pubmed: 27166395
Oncotarget. 2016 Apr 19;7(16):21527-41
pubmed: 26930717
F1000Res. 2016 Apr 19;5:
pubmed: 27134739
Clin Dev Immunol. 2012;2012:708036
pubmed: 22693526
Clin Cancer Res. 2013 Jun 15;19(12):3234-46
pubmed: 23620408
BMC Dev Biol. 2010 Jun 02;10:60
pubmed: 20525219
PLoS One. 2006 Dec 20;1:e15
pubmed: 17183641
Clin Cancer Res. 2010 Jun 15;16(12):3113-20
pubmed: 20530701
Cell Mol Life Sci. 2012 Oct;69(20):3429-56
pubmed: 22945800
Oncogene. 2008 Nov 24;27(55):6958-69
pubmed: 19029937
Tumour Biol. 2017 Mar;39(3):1010428317692248
pubmed: 28345458
Nat Biotechnol. 2010 Jun;28(6):611-5
pubmed: 20512123
Gastroenterology. 2012 Jul;143(1):234-45.e7
pubmed: 22510202
Gastroenterology. 2015 Nov;149(6):1553-1563.e10
pubmed: 26170137
Cell Stem Cell. 2015 Mar 5;16(3):225-38
pubmed: 25748930
Cancer Res. 2014 Mar 1;74(5):1566-75
pubmed: 24413534
Int J Oncol. 2014 Dec;45(6):2349-54
pubmed: 25269626
J Clin Invest. 2016 May 2;126(5):1745-58
pubmed: 27043282
J Biol Chem. 2012 Feb 3;287(6):3760-8
pubmed: 22170051
J Cell Sci. 2012 Oct 1;125(Pt 19):4417-22
pubmed: 23165231
Int J Oncol. 2014 Dec;45(6):2468-74
pubmed: 25269542
Mol Cancer Ther. 2014 Nov;13(11):2713-26
pubmed: 25249558
Cancer Sci. 2019 Nov;110(11):3520-3532
pubmed: 31505062
Mol Carcinog. 2014 Nov;53(11):893-906
pubmed: 23776059
J Cell Physiol. 2017 Dec;232(12):3261-3272
pubmed: 28079253
J Clin Invest. 2009 Jun;119(6):1417-9
pubmed: 19487817
PLoS One. 2017 Aug 30;12(8):e0184111
pubmed: 28854282
Clin Cancer Res. 2000 Sep;6(9):3719-28
pubmed: 10999766
Neoplasia. 2017 Jul;19(7):549-563
pubmed: 28601643
Am J Physiol Renal Physiol. 2006 May;290(5):F1202-12
pubmed: 16368739
Oncogene. 2016 Jun 2;35(22):2824-33
pubmed: 26387547